NCT06497361View on ClinicalTrials.gov

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Lupus NephritisIgG4-related Disease
Interventions
BIOLOGICAL

PRG-2311

PRG-2311 (CD19/BCMA-targeting CAR-T Cells)

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors
collaborator

Shenzhen Pregene Biopharma Co., Ltd.

INDUSTRY

lead

Tongji Hospital

OTHER